Additional Research. Institution and Principal Investigator shall not, without the prior written consent of Xxxxxxx, conduct any research nor facilitate third parties to conduct any research not required by the Protocol on (i) Trial Subjects during the Clinical Trial (including any additional research technique, procedure, questionnaire, or observation), or (ii) biological samples collected from Trial Subjects during the Clinical Trial, or (iii) the data derived from the Clinical Trial. Hereinafter, the research described in the previous sentence shall be referred to as “Additional Research”. In any case where Xxxxxxx gives such approval, the approved Additional Research shall be considered either an amendment to the original Protocol or shall be the subject of another written agreement between Janssen and Institution and Principal Investigator. Institution and Principal Investigator shall conduct all Additional Research in compliance with all applicable regulations, including requirements for obtaining appropriate EC approval and subject informed consent. Without limiting any other remedy available by law to Janssen, if Institution and/or Principal Investigator conducts Additional Research in breach of this section, and such Additional Research results in an Invention (as defined in Section 8 below), Institution and Principal Investigator (as applicable) hereby grant to Janssen or its designee an irrevocable, worldwide, paid up, royalty-free, exclusive license, with right of sublicense, to make, have made, use, have used, sell have sold, and import any such invention that results from such Additional Research. This Section shall survive termination or expiration of this Agreement. 1.10 Další výzkum: Poskytovatel ani hlavní zkoušející nebudou bez předchozího písemného souhlasu společnosti Janssen provádět žádný výzkum ani neumožní třetím osobám, aby prováděly výzkum, který není vyžadován protokolem, na (i) subjektech hodnocení během klinického hodnocení (včetně dalších výzkumných technik, postupů, dotazníků nebo pozorování), nebo (ii) biologických vzorcích odebraných subjektům hodnocení během klinického hodnocení, nebo (iii) údajích odvozených z klinického hodnocení. Výzkum popsaný v předchozí větě bude dále v této smlouvě označován jako „další výzkum“. V každém případě tam, kde společnost Xxxxxxx tento souhlas udělí, bude další výzkum považován buď za dodatek k původnímu protokolu, nebo bude předmětem další písemné dohody mezi společností Xxxxxxx a poskytovatelem a hlavním zk...
Additional Research. Institution and Principal Investigator shall not, without the prior written consent of Janssen, conduct any research nor facilitate third parties to conduct any research not required by the Protocol on (i) Trial Subjects during the Clinical Trial (including any additional research technique, procedure, questionnaire, or observation), or (ii) biological samples collected from Trial Subjects during the Clinical Trial, or (iii) the data derived from the Clinical Trial. Hereinafter, the research described in the previous sentence shall be referred to as “Additional Research”. In any case where CRO or Janssen gives such approval, the approved Additional Research shall be considered either an amendment to the original Protocol or shall be the subject of another written agreement between Xxxxxxx and CRO and Institution and Principal Investigator. Institution and Principal Investigator shall conduct all Additional Research in compliance with all applicable regulations, including requirements for obtaining appropriate EC approval and subject informed consent. Without limiting any other remedy available by law to Janssen, if Institution and/or Principal Investigator conducts Additional Research in breach of this section, and such Additional Research results in an Invention (as defined in Section 8 below), Institution and Principal Investigator (as applicable) hereby grant to Janssen or its designee an irrevocable, worldwide, paid up, royalty-free, exclusive license, with right of sublicense, to make, have made, use, have used, sell have sold, and import any such invention that results from such Additional Research. This Section shall survive termination or expiration of this Agreement.
Additional Research. At any time following exercise of an Option for a Collaboration Target, Vertex may request that CRISPR provide additional Research services to Vertex, with respect to such Collaboration Target (“Additional Research”). Upon such request, the Parties will meet and discuss in good faith whether CRISPR is able to provide those services and a mutually-agreeable plan (the “Additional Research Plan”), including a timeline, and budget, which will be subject to the approval of the JRC (the “Additional Research Budget”) therefor; provided that CRISPR may, in its sole discretion, refuse to perform Additional Research. Vertex will reimburse CRISPR for Research Costs incurred in performing activities under the Additional Research Plan as provided in Section 7.4. CRISPR will provide Vertex with the results of any Additional Research promptly following the completion thereof.
Additional Research. Following the Research Term, upon Xxxxxx’s request for Company to conduct certain additional Research activities with respect to Licensed Agents and Products, the Parties will discuss in good faith and, if the Parties agree that Company will conduct such activities, agree on a plan (each, an “Additional Research Plan”) and budget (each, an “Additional Research Budget”) for such activities (the “Additional Research Activities”). If the Parties agree on the Additional Research Plan and Additional Research Budget, then Company, directly or through its Affiliates or Subcontractors engaged in accordance with Section 2.1.4, will use Commercially Reasonable Efforts to perform the Additional Research Activities in accordance with the Additional Research Plan, including the timelines set forth therein, and in a professional and timely manner. Company will, and will require its Affiliates and Subcontractors to, perform its obligations under the Additional Research Plan in compliance with Applicable Law. [***]. Vertex will reimburse Company in accordance with Section 5.8 for Company’s FTE Costs and Out-of-Pocket Costs incurred in conducting such Additional Research Activities in accordance with the Additional Research Plan and Additional Research Budget. The Parties may amend any Additional Research Plan and Additional Research Budget upon mutual consent.
Additional Research. The Parties acknowledge a common purpose of developing product(s) useful for the diagnosis, cure or treatment of certain blood cancers and their complications. Achieving this goal may require additional research and development efforts beyond those encompassed within the Research Program. The Parties agree to meet no less than ** days prior to the expiration or termination of this Agreement in order to (a) evaluate the progress of the Research Program, (b) discuss additional research and development opportunities resulting from the Research Program, (c) determine any mutual interest in either amending this Agreement and its associated Research Program or entering into a new agreement to further such additional research and (d) if mutually agreed upon, the Parties agree to negotiate in good faith any reasonable agreements as may be proposed by either Party.
Additional Research. PROACT Search shall provide ample research materials for the CLIENT to determine best practices in superintendent contracts and associated terms. These materials and other materials shared with CLIENT may be determined to be confidential in nature.
Additional Research. The parties may agree to work on one or more additional Research Projects from time to time by preparing a separate SOW for each such additional Research Project signed by both parties that sets forth, at a minimum, the scope of such Research Project, the Period of Performm1ce (as defined in Section 3 below), the cost estimates, projected budget, or other consideration to be paid, timetable, reporting, and such other information as is set forth for the first SOW attached hereto as Exhibit A-1, to the extent applicable. Each new SOW shall be attached as a separate Exhibit A-"X" to this Agreement.
Additional Research. Unless it is approved in writing by Sponsor, Institution and Principal Investigator shall not conduct any research not required by the Protocol for the conduct of the Clinical Trial at or by Institution (i) on Trial subjects during the Clinical Trial (including any additional or (ii) on biological samples collected from Trial subjects during the Clinical Trial or the data derived there from. Hereinafter, the research described in the previous sentence shall be referred to as “Additional Research”. In any case where Sponsor gives such approval, the approved Additional Research shall be considered an amendment to the original Protocol, or shall be the subject of another agreement, and Institution and Principal Investigator shall conduct all such research in compliance with all applicable regulations, including requirements for obtaining appropriate EC approval and subject informed consent. Further, if such research is conducted notwithstanding the foregoing restriction, Institution hereby grants to Sponsor an irrevocable, worldwide, paid up, royalty-free, exclusive license, with right of sub-license, to make, have made, use, have used, sell, have sold, and import any invention that results from such Additional Research. This Section shall survive termination or expiration of this Agreement.
Additional Research. Verenium and Licensee may agree to an additional research program whereby Verenium would screen Licensee’s libraries and/or Verenium’s proprietary Gene libraries for Genes of interest to Licensee […***…]. Any such additional research program would be conducted on terms to be mutually agreed in writing by the Parties.
Additional Research. Unless it is approved in writing by Sponsor, Institution and Principal Investigator shall not conduct any research not required by the Protocol for the conduct of the Clinical Trial at or by Institution (i) on Trial subjects during the Clinical Trial (including any additional or (ii) on biological samples collected from Trial subjects during the Clinical Trial or the data derived there from. Hereinafter, the research described in the previous sentence shall be referred to as “Additional Research”. In any case where Sponsor gives such approval, the approved Additional Research shall be considered an amendment to the original Protocol, or shall be the subject of another agreement, and Institution and Principal Investigator shall conduct all such research in compliance with all applicable regulations, including requirements for obtaining appropriate EC approval and subject informed consent a . Further, if such research is conducted notwithstanding the foregoing restriction, Institution hereby přípravkem a za vedení kompletní dokumentace o této činnosti. Zdravotnické zařízení je povinno neprodleně po jejím určení písemně oznámit společnosti PAREXEL jméno a příjmení uvedené osoby (osob) spolu s případnými kontaktními xxxxx. Hlavní zkoušející se zavazuje, že bude hodnocený léčivý přípravek odebírat z lékárny zdravotnického zařízení v souladu s Protokolem a v dávkách potřebných pro jednotlivé studijní vizity subjektů hodnocení Zdravotnické zařízení se zavazuje na základě žádosti ZADAVATELE nebo CRO provést/zajistit bezpečnou likvidaci nevyužitého studijního léčiva (jako nebezpečný odpad) v souladu s ustanovením platných zákonů. 1.6 Další výzkum: Není-li Zadavatelem písemně schváleno jinak, nebudou Zdravotnické zařízení a Hlavní zkoušející provádět výzkum nevyžadovaný Protokolem pro provádění Klinického hodnocení ve Zdravotnickém zařízení nebo Zdravotnickým zařízením (i) na Subjektech hodnocení během Klinického hodnocení (včetně jakýchkoliv dalších) nebo (ii) na biologických vzorcích odebraných od Subjektů hodnocení během Klinického hodnocení. V této Smlouvě bude výzkum popsaný v předchozí větě uváděn jako „Další výzkum“. V případě, kdy Zadavatel dá takový souhlas, bude schválený Další výzkum považován za dodatek k původnímu Protokolu nebo bude předmětem další smlouvy a Zdravotnické zařízení a Hlavní zkoušející budou provádět takový výzkum v souladu s platnými předpisy, včetně požadavků pro získání příslušného souhlasu Etické komise a informovaného souhlasu Subjek...
